Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,335,775
  • Shares Outstanding, K 268,112
  • Annual Sales, $ 2,169 M
  • Annual Income, $ 521,270 K
  • EBIT $ 800 M
  • EBITDA $ 829 M
  • 60-Month Beta 0.40
  • Price/Sales 5.29
  • Price/Cash Flow 22.15
  • Price/Book 5.29

Options Overview Details

View History
  • Implied Volatility 43.68% (+4.55%)
  • Historical Volatility 36.29%
  • IV Percentile 71%
  • IV Rank 44.12%
  • IV High 71.05% on 10/17/25
  • IV Low 22.08% on 02/12/25
  • Expected Move (DTE 21) 3.73 (9.01%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 797
  • Volume Avg (30-Day) 653
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 19,799
  • Open Int (30-Day) 25,169
  • Expected Range 37.67 to 45.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.66
  • Number of Estimates 8
  • High Estimate 0.79
  • Low Estimate 0.29
  • Prior Year 0.48
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.81 +1.32%
on 01/30/26
46.31 -10.71%
on 01/07/26
-2.69 (-6.11%)
since 12/30/25
3-Month
36.00 +14.86%
on 11/03/25
47.24 -12.47%
on 12/23/25
+2.41 (+6.19%)
since 10/30/25
52-Week
32.38 +27.70%
on 04/09/25
49.62 -16.67%
on 06/23/25
+8.42 (+25.57%)
since 01/30/25

Most Recent Stories

More News
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –

EXEL : 41.52 (-1.80%)
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal...

EXEL : 41.52 (-1.80%)
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

– STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response to therapy –

NTRA : 231.27 (-0.09%)
EXEL : 41.52 (-1.80%)
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026

– Presentation to be webcast on www.exelixis.com –

EXEL : 41.52 (-1.80%)
Is Incyte Stock Outperforming the Nasdaq?

Despite Incyte’s outperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

$NASX : 23,418.69 (-1.12%)
INCY : 99.88 (-1.19%)
EXEL : 41.52 (-1.80%)
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

- Event to Review R&D Progress and Outline Exelixis’ Strategy for Building Next-generation Oncology Franchises -

EXEL : 41.52 (-1.80%)
The Biotech Boom Gets a Trading Tool: How Direxion's Titans ETF Gives Access to the Sector's Top Performers

Amid the biotechnology sector's transformative era the Direxion Daily Biotech Top 5 Bull 2X ETF ($TBXU) offers traders a new, single-trade solution to gain 2X daily leveraged exposure to an e

ALNY : 337.73 (-2.61%)
EXEL : 41.52 (-1.80%)
GILD : 142.02 (+1.77%)
INSM : 157.33 (-0.31%)
UTHR : 468.71 (+0.22%)
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

– Presentations to be webcast on www.exelixis.com –

EXEL : 41.52 (-1.80%)
Exelixis: Q3 Earnings Snapshot

Exelixis: Q3 Earnings Snapshot

EXEL : 41.52 (-1.80%)
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted...

EXEL : 41.52 (-1.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 44.47
2nd Resistance Point 43.88
1st Resistance Point 43.08
Last Price 41.52
1st Support Level 41.69
2nd Support Level 41.10
3rd Support Level 40.30

See More

52-Week High 49.62
Fibonacci 61.8% 43.03
Last Price 41.52
Fibonacci 50% 41.00
Fibonacci 38.2% 38.97
52-Week Low 32.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar